Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients?

Transfusion

Volumn 55, Issue 1, 2015, Pages 51-54

  Fischer, Quentin ^a   Huisse, Marie Geneviève ^a   Voiriot, Guillaume ^a   Caron, Claudine ^b   Lepage, Laurent ^a   Dilly, Marie Pierre ^c   Nataf, Patrick ^a,d   Ajzenberg, Nadine ^a   Kirsch, Matthias ^a,d  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; INOTROPIC AGENT; OCTREOTIDE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR; ARGIPRESSIN[1 DEAMINO]; FIBRINOGEN; HEMOSTATIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARGON PLASMA COAGULATION; ARTICLE; ARTIFICIAL VENTILATION; CARDIOGENIC SHOCK; CASE REPORT; CONTINUOUS FLOW LEFT VENTRICULAR ASSIST DEVICE; COUNTERPULSATION; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL HEMORRHAGE; HEART TRANSPLANTATION; HUMAN; INTRAAORTIC BALLOON PUMP; ISCHEMIC CARDIOMYOPATHY; MALE; STOMACH ULCER; THROMBOSIS; ADVERSE EFFECTS; ANGIOGENESIS; ARTIFICIAL EMBOLISM; DRUG EFFECTS; HEART ASSIST DEVICE; HEART VENTRICLE; LASER COAGULATION; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; RECURRENT DISEASE;

AGED; COMBINED MODALITY THERAPY; DEAMINO ARGININE VASOPRESSIN; EMBOLIZATION, THERAPEUTIC; ERYTHROCYTE TRANSFUSION; FIBRINOGEN; GASTROINTESTINAL HEMORRHAGE; HEART VENTRICLES; HEART-ASSIST DEVICES; HEMOSTATICS; HUMANS; LASER COAGULATION; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; POSTOPERATIVE HEMORRHAGE; RECURRENCE; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

EID: 84920933309     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12788     Document Type: Article

References (17)

1. McMurray J, Adamopoulos S, Anker SD, et al.; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847.
2. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32: 141-156.
3. Bunte MC, Blackstone EH, Thuita L, et al. Major bleeding during HeartMate II support. J Am Coll Cardiol 2013; 62: 2188-2196.
4. Suarez J, Patel CB, Felker M, et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail 2011; 4: 779-784.
5. Coutance G, Saplacan V, Belin A, et al. Octreotide for recurrent intestinal bleeding due to ventricular assist device. Asian Cardiovasc Thorac Ann 2014; 22: 350-352.
6. Demirozu ZT, Radovancevic R, Hochman LF, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30: 849-853.
7. Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2012; 31: 715-718.
8. Kirsch M, Vermes E, Boval B, et al. Blood activation during long-term mechanical circulatory support. Pathol Biol (Paris) 2005; 53: 97-104.
9. Crawley JT, de Groot R, Xiang Y, et al. Unravelling the sissile bond: how ADAMTS 13 recognizes and cleaves von Willebrand factor. Blood 2011; 118: 3212-3221.
10. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009; 137: 208-215.
11. Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6: 517-526.
12. Loscalzo J,. From clinical observation to mechanism-Heyde's syndrome. N Engl J Med 2012; 368: 579-580.
13. Manginas A, Tsiavou A, Sfyrakis P, et al. Increased number of circulating progenitor cells after implantation of ventricular assist devices. J Heart Lung Transplant 2009; 28: 710-717.
14. Randi AM, Laffan MA, Starke RD,. Von Willebrand factor, angiodysplasia and angiogenesis. Mediterr J Hematol Infect Dis 2013; 5: e2013060.
15. Feldman D, Pamboukian SV, Teuteberg JJ, et al.; International Society for Heart and Lung Transplantation. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157-187.
16. Cushing M, Kawaguchi K, Friedman KD, et al. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion 2012; 52: 1535-1541.
17. Borel-Derlon A, Federici AB, Roussel-Robert V, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007; 5: 1115-1124.